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Abstract
Introduction: Since positive blood cultures are uncommon in patients with nosocomial pneumonia (NP), the
responsible pathogens are usually isolated from respiratory samples. Studies on bacteremia associated with
hospital-acquired pneumonia (HAP) have reported fatality rates of up to 50%. The purpose of the study is to
compare risk factors, pathogens and outcomes between bacteremic nosocomial pneumonia (B-NP) and
nonbacteremic nosocomial pneumonia (NB-NP) episodes.
Methods: This is a prospective, observational and multicenter study (27 intensive care units in nine European
countries). Consecutive patients requiring invasive mechanical ventilation for an admission diagnosis of pneumonia
or on mechanical ventilation for > 48 hours irrespective of admission diagnosis were recruited.
Results: A total of 2,436 patients were evaluated; 689 intubated patients presented with NP, 224 of them developed
HAP and 465 developed ventilation-acquired pneumonia. Blood samples were extracted in 479 (69.5%) patients, 70
(14.6%) being positive. B-NP patients had higher Simplified Acute Physiology Score (SAPS) II score (51.5 ± 19.8 vs. 46.6 ±
17.5, P = 0.03) and were more frequently medical patients (77.1% vs. 60.4%, P = 0.01). Mortality in the intensive care unit
was higher in B-NP patients compared with NB-NP patients (57.1% vs. 33%, P < 0.001). B-NP patients had a more
prolonged mean intensive care unit length of stay after pneumonia onset than NB-NP patients (28.5 ± 30.6 vs. 20.5 ±
17.1 days, P = 0.03). Logistic regression analysis confirmed that medical patients (odds ratio (OR) = 5.72, 95% confidence
interval (CI) = 1.93 to 16.99, P = 0.002), methicillin-resistant Staphylococcus aureus (MRSA) etiology (OR = 3.42, 95% CI =
1.57 to 5.81, P = 0.01), Acinetobacter baumannii etiology (OR = 4.78, 95% CI = 2.46 to 9.29, P < 0.001) and days of
mechanical ventilation (OR = 1.02, 95% CI = 1.01 to 1.03, P < 0.001) were independently associated with B-NP episodes.
Bacteremia (OR = 2.01, 95% CI = 1.22 to 3.55, P = 0.008), diagnostic category (medical patients (OR = 3.71, 95% CI = 2.01
to 6.95, P = 0.02) and surgical patients (OR = 2.32, 95% CI = 1.10 to 4.97, P = 0.03)) and higher SAPS II score (OR = 1.02,
95% CI = 1.01 to 1.03, P = 0.008) were independent risk factors for mortality.
Conclusions: B-NP episodes are more frequent in patients with medical admission, MRSA and A. baumannii
etiology and prolonged mechanical ventilation, and are independently associated with higher mortality rates.
Introduction
Since positive blood cultures are uncommon in nosoco-
mial pneumonia (NP) patients, the responsible pathogens
are usually isolated from respiratory samples [1-3]. Studies
on bacteremia associated with hospital-acquired pneumo-
nia (HAP) have reported fatality rates up to 50% [4,5].
Although the impact of methicillin resistance on the out-
comes of patients with Staphylococcus aureus bacteremia
has been extensively evaluated, little information exists on
the impact of the methicillin resistance of patients with
nosocomial bacteremic S. aureus pneumonia. A prospec-
tive study in a single institution reported recently that
methicillin-resistant S. aureus (MRSA) was associated with
bacteremic ventilator-associated pneumonia (VAP) and
that bacteremia significantly increased mortality in these
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any medium, provided the original work is properly cited.patients [6]. Whether these findings are generalizable to
other case mixes or institutions is unknown.
The response to VAP can be shown from compart-
mentalized forms that account for a local response with
minor systemic compromise, whereas systemic spillover
or escape of inflammation led to septic shock and bac-
teremia. Moreover, some microorganisms such as
S. aureus are more adherent than others [7] and are
more likely to develop bacteremia.
Because some intensive care units (ICUs) do not per-
form blood cultures as part of the diagnosis work in
patients with suspected NP and this information pro-
vides useful epidemiologic information on causative
organisms and resistance, we performed a secondary
analysis of a large multicenter cohort of patients with
NP [8]. The primary objective was to confirm whether
bacteremic nosocomial pneumonia (B-NP) had higher
mortality rates than nonbacteremic nosocomial pneu-
monia (NB-NP). Secondary objectives were to identify
which risk factors and pathogens were associated with
development of B-NP.
Materials and methods
Study population and design
The EU-VAP/CAP was a prospective, observational sur-
vey conducted in 27 ICUs from nine European countries
(Belgium, France, Germany, Greece, Italy, Ireland,
Portugal, Spain and Turkey). The principal investigator
contacted one coordinator in each country (national
coordinator) who then selected the participating centers
for its country. All patients requiring admission for a
diagnosis of pneumonia or on invasive mechanical venti-
lation for longer than 48 hours, irrespective of the diag-
nosis at admission, were included.
The target was the collection of data for 100 consecu-
tive admissions in each ICU. Data were collected by the
primary investigator in each site (see Acknowledgements
for list of investigators). The period of data collection
was between 6 and 12 months (depending on the size
and type of the participating ICUs). Patient demo-
graphics, primary diagnosis, ICU and hospital lengths of
stay, Simplified Acute Physiology Score (SAPS) II score
[9], duration of mechanical ventilation and outcome
(ICU mortality) were recorded for all patients.
Each clinical episode of pneumonia was described
separately. For patients with a clinical diagnosis of pneu-
monia, data collection included clinical signs, sepsis
severity (sepsis/severe sepsis/septic shock) [10] and
Sepsis-related Organ Failure Assessment score [11] for the
d a yo fa d m i s s i o nt ot h eI C Uf o rc o m m u n i t y - a c q u i r e d
pneumonia and HAP, and for the day of clinical suspicion
for VAP and microbiology.
The present study was approved by the Ethics Board
of the coordinating center (Clinical Research Ethics
Committee, Joan XXIII University Hospital, Tarragona,
Spain). The participating centers either received ethical
approval from their institutions or ethical approval was
waived. Informed consent was waived due to the obser-
vational nature of the study.
Definitions
Pneumonia was diagnosed when new, persistent pul-
monary infiltrates, not otherwise explained, appeared on
chest radiographs with the presence of local (purulent
respiratory secretions) and systemic signs of inflamma-
tory response (white blood cell count > 10,000/μl, or
increase in white blood cell count > 20% in the absence
of leukocytosis or fever).
Bacteremic pneumonia was defined as at least one
positive blood culture not related to another source of
infection and at least one positive respiratory sample
culture (obtained within 48 hours of each other if two
or more cultures). In addition, at least one of the micro-
organisms isolated in respiratory samples had to be iso-
lated in blood cultures, whereas all isolates in blood
cultures were required to grow in simultaneously
obtained respiratory samples to fit the complete defini-
tion of bacteremic pneumonia. This was only diagnosed
when respiratory and blood samples yielded the same
microorganism and both cultures were performed within
48 hours. Other growths in both respiratory and blood
cultures within this period were defined as inconsistent
microbiology.
Fever was defined as two or more consecutive mea-
surements > 38°C. Pneumonia was considered ventila-
tor-associated when it occurred 48 hours after starting
mechanical ventilation, and was defined as early-onset if
it started within 4 days of admission, in accordance with
the American Thoracic Society/Infectious Disease
Society of America guidelines [12]. Trauma was defined
as the presence of injury in more than one body area or
system, or the presence of major cranial trauma alone.
Prior antibiotic exposure was considered when a patient
received antimicrobial agents during the 15 days preced-
ing the NP episode, with the exception of antibiotics
administered for surgical prophylaxis [13]. Shock was
described as systolic blood pressure < 90 mmHg despite
adequate fluid resuscitation and need for vasopressor
agents. At least 48 hours of hospitalization in the
90 days before admission or current hospitalization for
> 4 days before the start of mechanical ventilation was
considered as prior hospitalization.
Microbiology
Quantitative or qualitative tracheal aspirates or broncho-
scopic examination using bronchoscopic-protected spe-
cimen brush samples or bronchoscopic bronchoalveolar
lavage samples was performed to obtain uncontaminated
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identification and susceptibility testing were performed
by standard methods.
Statistical analysis
Discrete variables were expressed as counts (percentage)
and continuous variables as the mean and standard
deviation, unless stated otherwise; all statistical tests
were two-sided. The threshold for statistical significance
was defined as P < 0.05. Differences in categorical
variables were calculated using a two-sided likelihood
ratio chi-square test or Fisher exact test, and the Mann-
Whitney U test or Kruskal-Wallis test were used for
continuous variables, when appropriate.
Backward logistic regression was used to assess the
risk factors for bacteremia. Variables significantly asso-
ciated with mortality in the univariate analysis were
entered into the model. In order to avoid spurious asso-
ciations, variables entered into the regression models
were those with a relationship in univariate analysis (P ≤
0.05) or a plausible relationship with the dependent vari-
able. Potential explanatory variables were checked for
collinearity prior to inclusion in the regression models
using tolerance and the variance inflation factor. Vari-
ables associated with bacteremia in univariate analysis
were included in a multivariate analysis for identification
of independent variables after adjustment for severity of
disease using SAPS II. To assess the effect of bacteremia
on mortality, a stepwise logistic regression was per-
formed adjusting for admission category and severity of
illness (SAPS II). Results are presented as the odds ratio
(OR) and 95% confidence interval (CI). Data analysis
was performed using SPSS for Windows 13.0.0 (SPSS,
Chicago, IL, USA).
Results
A total of 2,436 intubated patients were evaluated, and 689
developed NP (465 VAP and 224 HAP). Blood samples
were extracted in 479 (69.5%) patients, and 70 (14.6%) of
them were positive. Clinical and epidemiological data for
the current study cohort are detailed in Table 1. No signif-
icant differences were observed between B-NP patients
and NB-NP patients regarding age and male gender
(59.2 ± 15.4 years vs. 56.5 ± 18.9 years, P = 0.26 and 71.4%
vs. 68%, P = 0.67, respectively), but B-NP patients had
higher SAPS II score than NB-NP patients (51.5 ± 19.8 vs.
46.6 ± 17.5, P = 0.03). In terms of diagnostic category,
B-NP patients were more frequently medical patients than
NB-NP patients (77.1% vs. 60.4%, P = 0.01). B-NP patients
had more elapsed time between ICU admission and VAP
than NB-NP patients (7.3 ± 14.1 days vs. 4.9 ± 5.8 days,
P = 0.02).
No significant differences were observed in co-
morbidities between B-NP patients and NB-NP patients.
Although there were no differences in baseline co-mor-
bidities between B-NP patients and NB-NP patients and
the SAPS II score on the day of ICU admission was
higher in surgical patients than medical and trauma
patients (51.1 ± 17.3 vs. 48.4 ± 18.3 vs. 41.1 ± 15.7, P <
0.001), in the period prior to developing NP medical
patients had a higher SAPS II score than surgical and
trauma patients (44.9 ± 17.1 vs. 41.8 ± 15 vs. 38.5 ±
17.6, P < 0.02). A nonsignificant trend to positive blood
cultures was associated with prior antibiotic exposure
(21.2% vs. 13%, P = 0.07). No differences were found
regarding septic shock (39.7% vs. 35%, P = 0.35). No dif-
ference was found in performance of the diagnostic
technique between B-NP and NB-NP.
ICU mortality was significantly higher in B-NP
patients compared with NB-NP patients (57.1% vs. 33%,
P < 0.001). B-NP patients had a more prolonged mean
ICU length of stay after pneumonia onset than NB-NP
patients (28.5 ± 30.6 days vs. 20.5 ± 17.1 days, P = 0.03)
(Table 2).
The pathogens isolated in blood cultures of B-NP are
presented in Table 3. The main pathogen isolated in
blood cultures of B-NP patients was MRSA (22.6%) fol-
lowed by Acinetobacter baumannii (17.9%). Respiratory
isolates for B-NP and NB-NP are detailed in Table 4.
Table 1 Clinical and epidemiological characteristics of
bacteremic and nonbacteremic nosocomial pneumonia
patients
Characteristic Bacteremic
(n = 70)
Nonbacteremic
(n = 409)
P value
Age (years) 59.2 ± 15.4 56.5 ± 18.9 0.26
Male gender 50 (71.4) 278 (68) 0.67
SAPS II score 51.5 ± 19.8 46.6 ± 17.5 0.03
Gap pneumonia 7.3 ± 14.1 4.9 ± 5.8 0.02
Diagnostic category at admission 0.01
Medical 54 (77.1) 246 (60.4)
Surgery 12 (17.1) 64 (15.7)
Trauma 4 (5.7) 97 (23.8)
Co-morbidities at admission
Diabetes mellitus 3 (4.3) 16 (3.9) 0.75
Hepatic cirrhosis 3 (4.3) 10 (2.4) 0.42
COPD 5 (7.1) 21 (5.1) 0.57
Chronic renal failure 10 (14.3) 32 (7.1) 0.34
CCI 9 (12.9) 29 (7.1) 0.15
Alcohol 0 (0) 17 (4.2) 0.15
Immunodepression 6 (8.6) 16 (3.9) 0.11
Relating to episode at admission
Septic shock 27 (39.7) 137 (35) 0.35
Prior antibiotic
exposure
15 (21.2) 53 (13) 0.07
Data presented as mean ± standard deviation or n (%). SAPS, Simplified acute
physiology score; Gap pneumonia, time between intensive care unit
admission and ventilator-associated pneumonia; COPD, chronic obstructive
pulmonary disease; CCI, congestive cardiac insufficiency.
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A. baumannii followed by MRSA. In contrast, the most
prevalent pathogen in NB-NP patients was Pseudomonas
aeruginosa followed by methicillin-susceptible S. aureus.
To identify independent risk factors for bacteremia, a
backward logistic regression included diagnostic cate-
gory, MRSA and A. baumannii etiology, duration of
mechanical ventilation, SAPS II score and prior antibio-
tic use. The model showed (Table 5) that medical
patients (OR = 5.72, 95% CI = 1.93 to 16.99, P =0 . 0 0 2 )
and surgical patients (OR = 5.06, 95% CI = 1.47 to
17.47, P = 0.01), compared with trauma patients, MRSA
(OR = 3.42, 95% CI = 1.57 to 5.81, P =0 . 0 1 ) ,
A. baumannii (OR = 4.78, 95% CI = 2.46 to 9.29, P <
0.001) and duration of mechanical ventilation (OR =
1.02 per day, 95% CI = 1.01 to 1.03, P < 0.001), were
independently associated with B-NP episodes.
A backward logistic regression to identify independent
risk factors for mortality showed that bacteremia was an
independent risk factor for ICU mortality (OR for death
= 2.01, 95% CI = 1.22 to 3.55, P = 0.008) after adjustment
for severity of illness. The SAPS II score (OR for death =
1.02 per point, 95% CI = 1.01 to 1.03, P = 0.008) and
diagnostic category (medical patients (OR for death =
3.71, 95% CI = 2.01 to 6.95, P = 0.02) and surgical
patients (OR for death = 2.32, 95% CI = 1.10 to 4.97,
P = 0.03)) were also independent variables associated
with ICU mortality (Table 6).
Discussion
The present analysis of a large, cohort, prospective, mul-
ticenter research study of NP reports that bacteremic
Table 2 Outcomes in bacteremic and nonbacteremic
nosocomial pneumonia patients
Bacteremic Nonbacteremic P value
ICU mortality 40 (57.1) 135 (33) <0.001
Survivors’ length of ICU stay
after pneumonia onset (days)
28.5 ± 30.6 20.5 ± 17.1 0.03
Survivors’ days of MV after
pneumonia onset (days)
19.5 ± 30.9 14 ± 15.7 0.11
Data presented as mean ± standard deviation or n (%). ICU, intensive care
unit; MV, mechanical ventilation.
Table 3 Organisms isolated in blood cultures of patients
with bacteremic nosocomial pneumonia
Isolate n (%)
Gram-positive
Methicillin-resistant Staphylococcus aureus 19 (22.6)
Methicillin-susceptible Staphylococcus aureus 11 (13.1)
Streptococcus pneumoniae 2 (2.4)
Gram-negative
Acinetobacter baumannii 15 (17.9)
Pseudomonas aeruginosa 12 (14.3)
Klebsiella species 11 (13.1)
Escherichia coli 7 (8.3)
Enterobacter species 5 (5.9)
Proteus mirabilis 1 (1.2)
Serratia species 1 (1.2)
Table 4 Isolates in respiratory samples of bacteremic and
nonbacteremic nosocomial pneumonia episodes
Isolate Bacteremic
(n = 117)
Nonbacteremic
(n = 378)
P value
Gram-positive
MSSA 13 (11.1) 55 (15.6) 0.29
MRSA 21 (18) 48 (12.7) 0.19
Streptococcus
pneumoniae
2 (1.8) 17 (4.5) 0.29
Gram-negative
Haemophilus influenzae 2 (1.8) 22 (5.8) 0.13
Pseudomonas
aeruginosa
17 (14.5) 67 (17.7) 0.51
Acinetobacter
baumannii
22 (18.8) 47 (12.4) 0.11
Escherichia coli 8 (6.8) 39 (10.3) 0.34
Enterobacter species 7 (6) 22 (5.8) 0.89
Klebsiella pneumoniae 15 (12.8) 22 (5.8) 0.02
Proteus species 2 (1.8) 9 (2.4) 0.98
Serratia species 1 (1) 7 (1.9) 0.8
Moraxella species 0 (0) 1 (0.3) 0.12
Stenotrophomonas
maltophilia
4 (3.5) 9 (2.4) 0.75
Morganella morgagnii 0 (0) 2 (0.5) 0.03
Citrobacter species 0 (0) 3 (0.8) <0.99
Burkholderia cepacia 0 (0) 1 (0.3) 0.12
Other GNB 1 (1) 5 (1.3) <0.99
Other anaerobic 1 (1) 2 (0.5) 0.09
Data presented as n (%). MRSA, methicillin-resistant Staphylococcus aureus;
MSSA, methicillin-susceptible Staphylococcus aureus; GNB, Gram negative
bacteria.
Table 5 Binomial logistic regression (multivariate)
analysis of risk factors associated with bacteremic
nosocomial pneumonia
Variable Wald value Exp(B) (95%
confidence interval)
P value
Constant 49.389
Diagnostic category
Medical 9.86 5.72 (1.93 to 16.99) 0.002
Surgical 6.58 5.06 (1.47 to 17.47) 0.01
Trauma 1
SAPS II 2.995 1.01 (0.99 to 1.03) 0.08
MRSA etiology 10.958 3.42 (1.57 to 5.81) 0.01
Acinetobacter etiology 21.287 4.78 (2.46 to 9.29) < 0.001
Duration of MV 12.434 1.02 (1.01 to 1.03) < 0.001
SAPS II, Simplified Acute Physiology Score; MRSA, methicillin-resistant
Staphylococcus aureus; MV, mechanical ventilation.
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patients. MRSA and A. baumannii (and medical condi-
tion on admission compared with trauma) were identi-
fied as independent risk factors for developing
bacteremia.
To our knowledge, this is the first prospective study
examining bacteremic episodes in critically ill patients
requiring mechanical ventilation due to NP. The present
study reports that 14.6% of NP episodes in European
ICUs have bacteremia. Our prevalence is within the
range (8 to 20%) of previous studies that included all
patients with NP not admitted to the ICU [14,15], but is
lower than that (17.3%) shown in the study of Agbaht
and colleagues that only included ICU patients with
VAP diagnosis [6].
The response to VAP might vary from compartmenta-
lized forms that account for a local response with minor
systemic compromise, whereas systemic spillover or
escape of inflammation led to septic shock and bacteremia.
VAP is characterized by an exuberant increase in procoa-
gulant activity, which precedes the clinical diagnosis of
VAP [16]. A well-known fact, confirmed by in vitro stu-
dies, is that S. aureus has a propensity to cause bacteremia.
These studies have demonstrated that S. aureus is more
adherent than other microorganisms because it exhibits a
high adherence manifested by the interaction of plasma
fibrinogen with the fibrinogen-binding proteins (the
clumping factor) [7]. Strains carrying the clumping factor
are known to cause more invasive diseases [17]. As fibri-
nogen is an acute-phase reactant that is frequently ele-
vated in critically ill patients, increased levels of this
molecule have been proposed to potentially increase its
adsorption onto the endothelial surface in susceptible
patients, thereby allowing more S. aureus to adhere
through the fibrinogen receptor [18]. Moreover, fibrin
deposits enhance inflammatory responses by increasing
vascular permeability, activating endothelial cells to pro-
duce proinflammatory mediators, and eliciting recruitment
and activation of neutrophils. One alternative explanation
may include the immunomodulating properties of S. aureus.
This pathogen constitutively has the possibility to release
enterotoxins that show superantigen activity and effectively
modify the functions of various inflammatory cells [19,20].
This stimulation may lead to inflammation, aggravating
airway disease in both the upper and lower respiratory
tracts. In our study, higher SAPS II score and bacteremia
were associated with high mortality rates that could be
explained by an abnormal inflammatory response which was
associated with poor outcomes.
The main pathogen isolated in blood samples of B-NP
patients was S. aureus (35.7%), including methicillin-sus-
ceptible S. aureus and MRSA, followed by A. baumannii
(17.9%). These results represent the same distribution
that Agbaht and colleagues reported in a matched case-
control study comparing bacteremic VAP versus
nonbacteremic VAP episodes [6]. S. aureus was the
pathogen most commonly associated with bacteremia.
This pathogen was also the most prevalent microbial
etiology (27%) in a prospective study of B-NP [13] and
the most prevalent (24%) in a cohort of 112 ICU
patients with B-NP [21].
The microbial etiology of HAP affected bacteremia
development, since both A. baumannii and, to a lesser
extent, MRSA were identified as independent predictors
of bacteremia even after adjustment for confounders.
A. baumannii exhibits an intrinsic resistance to multiple
antimicrobial agents and generates a continuing contro-
versy about whether VAP caused by this microorganism
increases morbidity and mortality independently of the
effect of other confounding factors in the ICU setting
[22-25]. In contrast to other studies [14,15], our data
show A. baumannii is an important pathogen isolated in
respiratory samples of B-NP patients and is also an
independent risk factor for bacteremia. A. baumannii
has a high level of antibiotic resistance, but with a low
virulence [25,26]. A recent study that compared risk fac-
tors and outcomes for bacteremia due to A. baumannii
and Klebsiella pneumoniae showed bacteremia due to
A. baumannii was significantly more frequent secondary
to NP than bacteremia due to K. pneumoniae [27].
Jamulitrat and colleagues showed that the observed
higher mortality rate among patients with an imipenem-
resistant A. baumannii bloodstream infection might not
be attributable to imipenem resistance but in some part
may be due to a more severe illness, inappropriate anti-
microbial therapy, and primary source of infection [28].
There are several factors linked with MRSA isolation
in VAP episodes: administration of antibiotics before the
development of VAP [29,30] and the length of hospital
stay rather than the period of mechanical ventilation
were strongly associated with MRSA isolation [31].
Methicillin resistance represents an independent risk
factor for a poor outcome, prolonged hospitalization
Table 6 Binomial logistic regression (multivariate)
analysis of risk factors associated with mortality in
bacteremic nosocomial pneumonia
Variable Wald value Exp(B) (95%
confidence interval)
P value
Constant 39.707
Diagnostic category
Medical 3.65 3.71 (2.01 to 6.95) 0.02
Surgical 2.34 2.32 (1.10 to 4.97) 0.03
Trauma 1
SAPS II 7.033 1.02 (1.01 to 1.03) 0.008
Gap pneumonia 0.518 1.01 (0.98 to 1.04) 0.472
SAPS II, Simplified Acute Physiology Score; Gap pneumonia: time between
intensive care unit admission and ventilator-associated pneumonia.
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therapy was appropriate [33]. Interestingly, new antimi-
crobial development and novel anti-adherence tools
based upon fibrinogen-binding protein derivatives [34]
might provide new opportunities to improve survival by
preventing bacteremic nosocomial pneumonia [35]. The
time to initiation of appropriate therapy with a molecu-
lar analysis of MRSA isolates and virulence factors
would be useful in future research.
Our results show that there is an independent associa-
tion between MRSA and A. baumannii etiology and
development of bacteremia in NP patients; but mortality
is associated with bacteremia and severity of disease.
These results confirm the concept shown in the study
by Agbaht and colleagues, since they also found an inde-
pendent association between MRSA and bacteremia but
mortality was associated with bacteremia rather with
MRSA [6]. In addition, the presence of bacteremia has
been identified as an independent risk factor for mortal-
i t yb yo t h e ra u t h o r sa n di n c l uded in clinical scores for
severity assessment of VAP episodes [36].
The present study has several strengths. Data were
generated from a multi-institutional study and represent
an interesting sampling from different European ICUs.
Our study enrolled patients prospectively and represents
a homogeneous population from critical care and
mechanically ventilated patients. The original approach
from our study was to consider all HAP episodes for
analysis since patients, especially those with VAP, have a
high chance of multiple drug-resistant pathogens, prior
antibiotic therapy and multiple co-morbidities.
The present study also has several potential limitations
that should be addressed. This study was observational
and non-interventional, in which the participating 27
ICUs from 9 countries were self-selected. The prescrip-
tion of antibiotics was chosen in accordance with the
protocol agreed by the institution. Second, the decision
to extract blood cultures was chosen in accordance with
local protocols and the physician’s clinical decision.
Although not all patients who developed NP underwent
blood cultures, in the present analysis two out of three
patients’ blood cultures were subsequently obtained.
There was case-mix difference between the participating
centers, but all types of ICU were represented with no
statistical differences found among bacteremic episodes.
We acknowledge that a matched cohort would be more
powerful to identify independent risk factors associated
with bacteremic episodes. Our analysis included, how-
ever, in a backward logistic regression model, all vari-
ables identified in univariate analysis and adjusted for
severity of disease. Although potential unknown con-
founding factors might be present, our model presented
an adequate goodness of fit.
Conclusions
The present study suggests that predisposition factors
such as diagnostic category at admission and infection-
related factors such as etiology are associated with
higher risk for B-NP. Recognition of these risk factors is
relevant for clinical practice, as bacteremia is an inde-
pendent risk factor for worse outcome in intubated
patients with NP. Our findings support the need to per-
form blood cultures in hospitalized patients with NP.
Key messages
￿ A total 14.6% of episodes of NP in the European
ICUs are bacteremic.
￿ The main pathogens isolated in blood cultures of
B-NP patients are MRSA and A. baumannii.
￿ Bacteremia is independently associated with a
higher mortality rates in patients with NP.
￿ B-NP episodes are more frequent in patients with
medical admission, MRSA and A. baumannii etiol-
ogy, and prolonged mechanical ventilation.
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